Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success

Eoneren Getting a new drug across the finish line to FDA approval is difficult enough in its own right – over 90% of drugs that enter into Phase I testing never make it – but approval is just one link in a chain of challenges. No drug sells itself or pays for itself, and it takes time and money to not only make doctors aware of the drug and motivated to use it, but also to get payors to reimburse for it. While Lexicon Pharmaceuticals (NASDAQ:LXRX) has managed to get two drugs onto the market, the launch of ...